Catalyst

Slingshot members are tracking this event:

Merrimack (MACK) Terminates Phase 2 HERMIONE Trial Evaluating MM-302 in HER2-Positive Locally Advanced or Metastatic Breast Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MACK

100%

Additional Information

Additional Relevant Details
  • Results from HERMIONE, the Phase 2 clinical study of MM-302 in patients with HER2-positive metastatic breast cancer designed to support a potential Accelerated Approval application to the FDA, in 2017
http://investors.mer...
Additional Relevant Details Updated December 21st, 2016: Phase 2 data originally due in 2017
http://investors.mer...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 21, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Data, Mm-302, Hermione, Her2-positive Breast Cancer